Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02926638
Status:
TERMINATED
Last Update Posted:
2020-03-19
First Post:
2016-05-06
Brief Title:
Lung-MAP Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Organization Data
Organization:
SWOG Cancer Research Network
Class:
NETWORK
Study ID:
S1400E
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
SWOG Cancer Research Network
Lead Sponsor Class:
NETWORK
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| National Cancer Institute NCI | NIH |